- EDITIONS: Spanish News Today Murcia Today Alicante Today
Date Published: 30/07/2021
ARCHIVED - Cadiz hospital trials new Covid treatment in international study
The Puerto Real University Hospital, Cádiz, is the only centre in Andalucía to participate in the trial
The Infectious Diseases Unit at the Puerto Real University Hospital in Cádiz is participating in an international clinical trial exploring the efficiency of a new treatment for Covid-19.
Hospitals and medical centres from 12 different countries are participating in the trial, including 11 Spanish hospitals, of which only one is in the Andalucía region.
The study is a double-blind RCT (randomised controlled trial) which aims to prove the effectiveness of the use of inhaled interferon beta 1 in mild-to-moderate cases of Covid.
Interferon beta 1 belongs to a type of medication called immunomodulators, which is frequently used in the treatment of multiple sclerosis symptoms as it decreases inflammation and prevents nerve damage.
This medication will be applied to coronavirus patients using an electronic device that nebulises the drug and allows it to be inhaled.
Since its creation less than a year ago, the investigation department of the Infectious Diseases Unit at Puerto Real Hospital has participated in seven clinical trials; four about Covid-19, one about HIV and two about antibiotic resistant bacteria.
Representatives from the hospital have stated that this opportunity allows the rising number of coronavirus patients in Cádiz to be offered a promising treatment for Covid that isn’t available anywhere else.
IMAGE: Archive
staff.inc.and
Loading
Read more about Coronavirus:
OR
Sign up for the Spanish News Today Editors Roundup Weekly Bulletin to get a comprehensive email with all the week’s news for Spain, Murcia, Alicante and Andalucía.
Get a sneak peek – here are a few of our recent Subscription Bulletins:
50% Discount Special Offer subscription:
24.95€ for 48 Editor’s Weekly News Roundup bulletins!
Please CLICK THE BUTTON to subscribe.
Contact Murcia Today: Editorial 966 260 896 /
Office 968 018 268